Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is GSK's depemokimab, a long-acting anti-IL-5 antibody for severe asthma and an ...
GSK has claimed approval in the EU for Exdensur, a long-acting respiratory drug that is considered one of its top growth prospects. The approval of Exdensur (depemokimab) for severe asthma and chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results